Two drugs have decades of independent, replicated trial data behind them for male pattern hair loss, minoxidil and finasteride. Everything else marketed to men falls somewhere on a spectrum between "genuinely promising" and "actively debunked," and most product labels don't bother telling you which end of that spectrum you're buying into.

I've organized this piece the way I'd want a patient to see the evidence organized: proven, promising, or debunked, based on what the actual trial data supports rather than what a bottle claims. Every citation traces to a peer-reviewed source on PubMed, and where a treatment's real-world use outpaces its evidence, that gap gets named directly.

How This Grading Works

A treatment lands in the proven tier only with a large, independently replicated body of randomized controlled trial data behind it, not one manufacturer-funded study. The bar for promising is lower but still real: human trial data exists, though the evidence base might be thinner, smaller in scale, still developing, or complicated by a regulatory gap between what's approved and how the treatment actually gets used in practice. Debunked means the claim has either been directly tested and failed, or has no plausible biological mechanism and no supporting trial data despite wide circulation online. Being unstudied isn't the same thing as being debunked. A treatment can start out understudied and climb a tier once research catches up, which looks nothing like a claim that already got tested and came up short.

Proven: Minoxidil and Finasteride

Independent replication is where minoxidil pulls ahead of everything else covered here. One 48-week trial put 5% and 2% topical concentrations head to head, and the higher dose finished roughly 45% ahead on hair regrowth by direct hair count in a defined scalp area. Minoxidil earned its FDA approval for mild-to-moderate androgenetic hair loss the hard way, through decades of studies run by different research groups rather than a single sponsor's data. None of that makes it effortless to use. Daily application has to continue indefinitely, and a minority of users go through an initial shedding phase or scalp irritation before anything improves.

Testosterone gets converted into DHT by an enzyme, and finasteride blocks that enzyme directly. DHT itself is the hormone most responsible for shrinking genetically susceptible follicles, which is why blocking its production upstream works differently than minoxidil's approach of widening blood vessels near the follicle. Proof of this came from 1,553 men tracked for two years in the trial that established finasteride's use. Hair-count gains over placebo were statistically real, and they kept building through year two rather than leveling off early. A prescription is required, and while sexual side effects are uncommon, they're common enough that a prescriber should be the one having that conversation, not a pharmacy label. Stopping either drug reverses its gains within months, since neither one touches the underlying genetic sensitivity to DHT, only the downstream consequences of it.

Promising: Dutasteride, Laser Therapy, Ketoconazole, and PRP

Finasteride blocks one form of the DHT-converting enzyme. Dutasteride blocks both. Nine hundred seventeen men took part in the trial that tested this fuller blockade directly, split between dutasteride, finasteride, and placebo over 24 weeks, and dutasteride pulled ahead on hair count without a notably worse side-effect profile. So why isn't it the default choice in the US? Approval, not biology, is the answer. The FDA cleared dutasteride for enlarged prostate, never for hair loss, which leaves American men using it for AGA in off-label territory despite trial data that's arguably stronger than finasteride's own. South Korea took a different regulatory path and approved it specifically for hair loss years ago, a reminder that the gap here is bureaucratic timing, not a gap in what the science actually shows.

Low-level laser therapy uses red or near-infrared light to stimulate follicles, and the evidence has strengthened considerably in recent years. Eight studies and eleven randomized controlled trials went into a recent meta-analysis, and laser treatment came out ahead of sham devices on hair density by a significant margin. The appeal is that it's passive, worn as a cap or run through the hair for a set number of minutes daily rather than requiring a daily pill or messy application, though device quality varies widely, and only a subset of products marketed under the LLLT label actually carry FDA clearance.

Ketoconazole shampoo started out as an antifungal treatment, and a long-term study on men using the 2% formula found real improvement in hair density in men who had no dandruff to explain the effect away. Reducing scalp inflammation looks like the more likely mechanism here, rather than any direct action on DHT. Dandruff and fungal infections are what the FDA actually cleared this shampoo for. Hair growth sits outside that approval, which makes this use technically off-label no matter how supportive the research looks. Two to three applications a week, layered alongside minoxidil or finasteride, is the more common way dermatologists actually recommend it rather than as a standalone fix.

A patient's own blood becomes the treatment here: drawn, concentrated down to its platelets, and injected back into the scalp to stimulate follicles directly. Reviewing PRP against minoxidil, finasteride, and stem-cell-based therapies, a systematic review landed on a genuinely favorable verdict for androgenetic alopecia. Consistency is where the field still struggles, though. Protocols and platelet concentrations varied enough across the studies that review covered to make cross-clinic comparisons genuinely difficult, so one provider's "PRP" isn't automatically the same product as another's. A course of treatment usually means several sessions weeks apart, then maintenance visits after that, at a price that shifts a lot depending on the clinic.

Debunked: Common Claims That Don't Hold Up

Correlation explains the hat myth better than causation does. Men already losing hair reach for hats more often, to cover it, and that pattern gets misread as hats causing the problem rather than responding to it. No mechanism exists by which ordinary hat wear would meaningfully restrict blood flow to a follicle sitting under the scalp's skin.

Shampooing frequency works similarly. Hair already sitting in its shedding phase comes loose during a wash regardless of how often that wash happens, so a fuller-looking drain after a shower reads as "shampoo pulled my hair out" when really the hair was coming out anyway. Skip the wash, and those same hairs shed somewhere else instead, a hairbrush or a pillow, rather than staying put.

Deficiency is the whole story with biotin, and most men don't have one. Correcting an actual biotin deficiency does help hair growth in that specific case, since biotin genuinely matters for keratin production. True deficiency shows up rarely in men eating an ordinary diet, though, which means a biotin gummy marketed broadly at hair loss is selling a fix for a problem most buyers don't actually have.

Natural remedies marketed as complete replacements for medication, pumpkin seed oil capsules, saw palmetto alone, rosemary oil alone, deserve a more careful distinction than "works" or "doesn't work." Several of these ingredients do have real trial data behind them in isolation. None of them has been shown to match minoxidil or finasteride's effect size in a head-to-head comparison, so treating any single one as a full substitute for a proven medication oversells what the evidence actually supports.

Scalp massage devices, used alone with no other active ingredient or medication, have essentially no independent trial data supporting meaningful regrowth on their own. The theory behind them, increased blood flow to the follicle through mechanical stimulation, is plausible in principle, but plausible mechanisms and demonstrated results are different things, and no large controlled trial has actually confirmed a massage-only device produces regrowth comparable to an established treatment. Massage may have a modest supporting role alongside a real treatment, but marketing it as sufficient on its own isn't backed by the kind of evidence this article otherwise requires.

Where MDhair's Protocol Maps to the Proven Tier

An AI scalp assessment identifies which combination of causes, genetic, hormonal, inflammatory, is most likely behind a given man's hair loss, and MDhair's regimen gets built around medicated minoxidil where it's clinically appropriate, the same proven active discussed above rather than a proprietary substitute. The kit pairs that with DHT-blocker serums and supplements matched to the identified cause, plus unlimited dermatologist support to adjust the regimen as things change over the following months and years.

I ran the underlying trial myself, six months, IRB-approved, on the full MDhair regimen. Hair growth came in at roughly 2.8 times a leading supplement competitor. Hair quality landed around 3.0 times that same competitor. Both figures held at the p<0.01 level. A separate measurement tracked something the growth numbers alone don't capture: scanning electron microscopy of the hair shaft. Grade 2 cuticle damage, the visible cracking kind, moved down to Grade 0, smooth and intact, over that same window. A personalized, multi-part regimen working together is what this data actually shows, not one proprietary ingredient somehow beating minoxidil or finasteride solo.

What's Actually Regulated Here

Two genuine FDA-approved drugs are discussed here, minoxidil and finasteride, both cleared specifically for mild-to-moderate androgenetic hair loss. Dutasteride and ketoconazole shampoo are prescription and OTC drugs too, just approved for other conditions entirely, so their use for hair loss specifically sits outside their original indication. Everything else in this piece, supplements, serums, cosmetic formulations, lives in a different category altogether. None of it has gone through FDA evaluation the way an active drug ingredient has. None of it is meant to diagnose, treat, cure, or prevent disease, whatever a label might imply.

A prescriber's a good idea before starting finasteride or dutasteride, given the sexual side-effect profile both carry. The same goes for anyone layering a new treatment on top of an existing medical condition. And if a topical product starts irritating the scalp, the smarter move is pausing to reassess rather than gritting through it.

Where This Leaves You

Minoxidil and finasteride remain the two options with genuine, decades-deep independent evidence behind them, and they're still the reasonable starting point for most men dealing with genetic hair loss. Dutasteride, laser therapy, ketoconazole, and PRP each add real value for specific situations, without quite matching that first tier's evidence depth. The debunked claims persist mostly because they're cheap, easy, and require no prescription, not because the research supports them.

What none of these options do automatically is identify which combination is actually right for a given man's specific case. That's the gap a proper scalp assessment closes, and it's why MDhair builds its protocol around the proven tier first rather than starting with whatever ingredient is trending.

Sources

1. Bhardwaj V, Rodgers N, Harth O, Harth Y. Artificial Intelligence-Based Personalization of Treatment Regimen for Hair Loss: A 6-Month Clinical Trial. J Drugs Dermatol. 2025;24(3):233-238. doi:10.36849/JDD.8611

2. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385.

3. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589.

4. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-1023.

5. Afifi L, et al. Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a systematic review and meta-analysis. PubMed (PMID: 30706177).

6. Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole Shampoo: Effect of Long-Term Use in Androgenic Alopecia. Dermatology. 1998;196(4):474-477.

7. Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with Minoxidil, Finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.

Find the most effective hair growth products for you by taking the free hair assessment.